Pharma lobby obtains stay on Centre’s drug price control order

Drug manufacturers also trying to scuttle government’s drug pricing policy

Court revoking ban on cough remedy worries health activists

They say continuing availability of the drug poses health risk

COVID-19: India trips on its patent waiver proposal

New Delhi has not backed its WTO proposal to suspend intellectual property rights on COVID-19 pharma products with robust action

Pharma’s dirty deals to stall generics

As generic companies, including Indian firms, collude with innovator pharma giants in pay-for-delay pacts, consumers pay a high price

High Court notice to Novartis on Cipla appeal

Cipla has challenged the court order restraining it from manufacturing generic version of respiratory ailment drug

Can vaccines become as cheap as generics?

Unlike with drugs, freeing up patents will not make it any easier to manufacture vaccines for COVID-19, says Cipla’s Hamied

Cipla set to launch repurposed drug Favipiravir for COVID-19: CSIR

An off-patent anti-viral, Favipiravir was originally discovered by Fujifilm group, Japan and has shown promise in treatment of COVID-19

A victory and a retreat on CLs

Supreme Court upholds India's first compulsory licence but government baulks at giving the second

Rethinking IP think tank

Government sidelines its committee of experts to set up new panel to review India's intellectual property rights policy

Cipla's audacious move

Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug

The world needs pharmaceuticals from China and India to beat COVID-19

Chinese manufacturers make around 40% of all APIs used worldwide; China, India are the source of 75-80% of APIs imported to US

COVID-19: Centre doesn’t clarify basis for CDSCO authorising remdesivir

Government also does not provide clarity about whether remdesivir should be given to only severe patients

Novartis loses patent appeal in landmark suit

Supreme Court upholds amended law that bars patents for insignificant improvements to an existing drug—in this case anti-cancer drug …